Ilaris® Approved By FDA To Treat Active Systemic Juvenile Idiopathic Arthritis, A Ser

Ilaris® (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection1...

More...